ACADIA Pharmaceuticals Inc. ACAD

ACAD Company Overview

ACADIA Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders and rare diseases. The company operates primarily within the biotechnology and specialty pharmaceutical industries, with an emphasis on neurological and neuropsychiatric conditions that have limited treatment options. Its revenue is primarily derived from commercialized prescription therapies and related licensing activities.

The company’s principal products include NUPLAZID (pimavanserin), approved for hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE (trofinetide), approved for Rett syndrome. ACADIA has also maintained clinical development programs targeting additional neurological and psychiatric indications. The company positions itself within highly specialized therapeutic markets where unmet medical need, orphan-drug opportunities, and physician specialization can support differentiated pricing and market access. Founded in 1993 and headquartered in San Diego, California, ACADIA evolved from an early-stage neuroscience research company into a commercial-stage biopharmaceutical business following the U.S. regulatory approval and launch of NUPLAZID.